Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 3/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295947 | 0.84 | S1PR2 (0.36) | S1PR1S1PR3S1PR2LPAR2SMN1; SMN2 | |
| SCHEMBL295746 | 0.81 | NPC1 (0.34) | S1PR1S1PR3S1PR2LPAR2SMN1; SMN2 | |
| SCHEMBL13851949 | 0.80 | S1PR1 (0.52) | S1PR1S1PR3THRATHRBS1PR4 | |
| SCHEMBL296184 | 0.79 | S1PR2 (0.48) | S1PR1S1PR3S1PR2LPAR2SMN1; SMN2 | |
| SCHEMBL295593 | 0.79 | SMN1; SMN2 (0.41) | S1PR1S1PR3S1PR2LPAR2SMN1; SMN2 | |
| SCHEMBL86787 | 0.76 | AAK1 (0.41) | S1PR1S1PR3S1PR4S1PR5AAK1 | |
| SCHEMBL13614222 | 0.76 | CA12 (0.43) | AAK1 | |
| SCHEMBL295920 | 0.73 | S1PR1 (0.37) | S1PR1S1PR3S1PR2LPAR2SMN1; SMN2 | |
| SCHEMBL295921 | 0.73 | S1PR1 (0.37) | S1PR1S1PR3S1PR2LPAR2SMN1; SMN2 | |
| SCHEMBL3738559 | 0.72 | ALDH1A1 (0.39) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636171-B1 | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-7696184-B2 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20070010494-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | NOVARTIS AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010494-A1 | Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.